secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001558370-24-000136
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte reports prelim Q4 total revenue $15.5-15.7M, core down YoY; FY total revenue $41.1-41.3M
--------------------------------------------------------------------------------

- Q4 2023 total revenue expected $15.5-15.7M (Q4 2022: $12.4M); core revenue $7.0-7.2M (down from $10.6M) and SPL revenue ~$8.5M (up from $1.9M).
- FY 2023 total revenue expected $41.1-41.3M (FY 2022: $44.3M); core revenue $29.6-29.8M (down from $39.6M), SPL ~$11.4M (up from $4.6M).
- Cash, equivalents and investments ~$210M as of Dec 31, 2023.
- Management cited Vertex CASGEVY FDA approval as milestone validating platform; core revenue decline reflects cell therapy industry headwinds.
- Results are preliminary, unaudited; audited statements expected in March 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024000136/0001558370-24-000136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024000136/mxct-20240108x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer